Table 2.
Univariate Conditional Logistic Regression Predictors of VTE in Prophylaxed Patients
| Variable* | VTE (n = 94) N (%) |
No VTE (n = 272) N (%) |
OR / Mean Difference | 95% CI | p Value |
|---|---|---|---|---|---|
| Demographics | |||||
| Age (mean years ± SD) | 62.5 (16.6) | 62.6 (16.6) | 0.2 | −3.7 to 4.0 | 0.94 |
| Female Gender | 43 (45.7) | 149 (53.2) | 0.7 | 0.5–1.2 | 0.21 |
| Non-White Race* | 18 (19.2) | 68 (24.3) | 0.7 | 0.4–1.3 | 0.30 |
| BMI (anti-log mean)** | 28.2 | 27.8 | 1.0 | 1.0–1.1 | 0.57 |
| Current Smoker | 12 (12.8) | 53 (18.9) | 0.6 | 0.3–1.2 | 0.15 |
| Length of Stay (LOS) until VTE (anti-log mean days) | 6.3 | 4.6 | 1.4 | 1.2–1.6 | < 0.001 |
| Cancer | |||||
| Active Cancer (reference never or history of cancer) | 16 (17.0) | 46 (16.4) | 1.1 | 0.6–2.0 | 0.87 |
| History of Cancer (reference never or active cancer) | 3 (3.2) | 44 (15.7) | 0.2 | 0.1–0.6 | 0.01 |
| Chemotherapy | 4 (4.3) | 17 (6.1) | 0.7 | 0.2–2.1 | 0.50 |
| Other Comorbid Conditions | |||||
| Acute Respiratory Failure | 8 (8.5) | 9 (3.2) | 2.7 | 1.0–6.9 | 0.04 |
| Chronic Obstructive Pulmonary Disease (COPD) | 8 (8.5) | 40 (14.3) | 0.6 | 0.3–1.3 | 0.17 |
| Congestive Heart Failure (CHF) | 15 (16.0) | 36 (12.9) | 1.3 | 0.7–2.5 | 0.43 |
| Diabetes | 24 (25.5) | 84 (30.0) | 0.8 | 0.5–1.4 | 0.42 |
| Hypertension | 51 (54.3) | 181 (64.6) | 0.6 | 0.3–1.0 | 0.04 |
| Myocardial Infarction (MI) | 5 (5.3) | 6 (2.1) | 2.7 | 0.8–9.5 | 0.12 |
| Peripheral Artery Disease | 6 (6.4) | 14 (5.0) | 1.3 | 0.5–3.6 | 0.59 |
| Stroke | 3 (3.2) | 3 (1.1) | 3.0 | 0.6–14.9 | 0.18 |
| Neurological Disease | 13 (13.8) | 27 (9.6) | 1.5 | 0.7–3.2 | 0.24 |
| Renal Disease | 18 (19.2) | 52 (18.6) | 1.1 | 0.6–2.0 | 0.88 |
| Spinal Cord Injury | 3 (3.2) | 1 (0.4) | 9.0 | 0.9–86.5 | 0.06 |
| Extremity Paresis or Plegia | 9 (9.6) | 10 (3.6) | 2.8 | 1.1–7.4 | 0.04 |
| VTE in Prior Year | 6 (6.4) | 8 (2.9) | 2.3 | 0.8–6.5 | 0.13 |
| Infection | |||||
| Any Infection | 29 (30.9) | 36 (12.9) | 2.8 | 1.6–4.9 | < 0.001 |
| Blood Infection | 13 (13.8) | 9 (3.2) | 5.7 | 2.1–15.0 | < 0.001 |
| Blood Culture Ordered | 21 (22.3) | 16 (5.7) | 5.0 | 2.4–10.4 | < 0.001 |
| First leukocyte count > 13,000/mm3 | 39 (41.5) | 52 (19.1) | 3.1 | 1.8–5.2 | < 0.001 |
| Surgery | |||||
| Surgery | 47 (50.0) | 101 (36.1) | 1.9 | 1.2–3.2 | 0.01 |
| > 1 Surgery | 14 (14.9) | 5 (1.8) | 10.0 | 3.3–30.6 | < 0.001 |
| Cranial Surgery | 14 (14.9) | 3 (1.1) | 14.0 | 4.0–48.7 | < 0.001 |
| Non-Cranial Surgery | 33 (35.1) | 98 (35.0) | 1.0 | 0.6–1.7 | 0.94 |
| Craniospinal Surgery | 8 (8.5) | 15 (5.4) | 1.7 | 0.7–4.0 | 0.27 |
| Orthopedic Surgery | 7 (7.5) | 23 (8.2) | 0.9 | 0.4–2.2 | 0.83 |
| Other Surgery | 19 (20.2) | 60 (21.4) | 0.9 | 0.5–1.7 | 0.82 |
| Trauma | 17 (18.1) | 15 (5.4) | 3.6 | 1.7–7.4 | < 0.001 |
| Transfusion | |||||
| Fresh Frozen Plasma (FFP) Transfusion | 10 (10.6) | 9 (3.2) | 3.8 | 1.4–10.2 | 0.01 |
| Packed Red Blood Cells (PRBCs) Transfusion | 37 (39.4) | 47 (16.8) | 3.2 | 1.9–5.3 | < 0.001 |
| PRBCs Transfusion in first 48 hours of admit | 16 (17.0) | 38 (13.6) | 1.3 | 0.7–2.5 | 0.39 |
| Platelet Transfusion | 6 (6.4) | 7 (2.5) | 3.0 | 0.9–10.1 | 0.08 |
| FFP, PRBCs, or Platelet Transfusion | 40 (42.6) | 56 (20.0) | 2.9 | 1.8–4.8 | <0.001 |
| Laboratory | |||||
| First Platelets count < 140,000/mm3 | 14 (14.9) | 46 (16.4) | 0.9 | 0.5–1.8 | 0.73 |
| First Prothrombin Time (PT) > 15.7 seconds | 31 (33.0) | 64 (22.9) | 1.7 | 1.0–3.0 | 0.05 |
| First Partial Thromboplastin Time (PTT) > 36.0 sec | 19 (20.2) | 48 (17.1) | 1.2 | 0.7–2.3 | 0.47 |
| Medications | |||||
| Antiplatelet | 27 (28.7) | 103 (36.8) | 0.7 | 0.4–1.2 | 0.15 |
| Thrombogenic prescription | 9 (9.6) | 18 (6.4) | 1.7 | 0.7–4.2 | 0.27 |
| Miscellaneous | |||||
| Admitted from Chronic or Long Term Care (LTC) | 36 (38.3) | 49 (17.5) | 3.2 | 1.8–5.7 | < 0.001 |
| Any Bedrest (including with bathroom privileges) | 45 (47.9) | 80 (28.6) | 2.4 | 1.5–4.0 | < 0.001 |
| Critical Care Patient | 54 (57.5) | 47 (16.8) | 7.0 | 4.0–12.5 | < 0.001 |
| Indwelling Central Venous Catheter (CVC) | 60 (63.8) | 75 (26.8) | 4.8 | 2.9–8.0 | < 0.001 |
*
Non-White Race: No VTE group includes 2 Asian and 3 Other Race patients
**
BMI: excludes 30 control patients with missing height and/or weight data
†
WBC: excludes 8 control patients with no WBC lab